In clinical applications, it has been found that severe COVID-19 patients presenting with ARDS lead to an increase in pro-inflammatory factors, most notably interleukin 1β (IL-1β), interleukin-6 (IL-6), and TNF (Anka et al., 2021). The gene discussed is IL6; the disease is COVID-19.